Parameter

Rivastigmine, N = 25

Rivastigmine plus RSC, N = 27

Statistic values

Sex (male/female)-no.

11/14

16/11

x² = 1.211; p = 0.271

Age (mean ± SD)

69.7 ± 4.2

70.6 ± 6.9

t = 0.571; p = 0.570

Education (mean ± SD)

9.1 ± 2.1

8.9 ± 3.1

t = 0.316; p = 0.753

Duration of PD (mean ± SD)

7.9 ± 1.9

7.8 ± 2.4

t = 0.292; p = 0.771

Duration of PDD (mean ± SD)

1.6 ± 0.9

1.6 ± 0.8

t = 0.044; p = 0.965

MMSE score (mean ± SD)

20.8 ± 3.9

19.8 ± 3.8

t = 0.283; p = 0.778

ADAS-cog score (mean ± SD)

25.4 ± 9.4

26.2 ± 9.1

t = 0.320; p = 0.750

ADL score (mean ± SD)

42.6 ± 9.3

42.1 ± 11.0

t = 0.173; p = 0.863

UPDRS part III score (mean ± SD)

33.6 ± 11.1

33.3 ± 12.5

t = 0.092; p = 0.927

Medications used-no. (%)

Levodopa Dopamine agonists Amantadine Comtan Antidepressants Antianxiety agents Antipsychotic agents

24 (96%)

19 (76.0%)

9 (36.0%)

4 (16.0%)

7 (28.0%)

8 (32.0%)

8 (32.0%)

25 (92.6%)

22 (81.5%)

7 (25.9%)

3 (11.1%)

6 (22.2%)

10 (37.0%)

9 (33.3%)

x² = 0.277; p = 0.599 x² = 0.234; p = 0.629 x² = 0.618; p = 0.432 x² = 0.266; p = 0.606 x² = 0.231; p = 0.631 x² = 0.146; p = 0.703 x² = 0.010; p = 0.918